Recent Posts

Lead Researcher Highlights Tisagenlecleucel Benefit in Younger Leukemia Patients

The CD19-targeted CAR T-cell therapy, tisagenlecleucel (Kymriah) demonstrated durable remissions in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL).

Read more: https://www.onclive.com/web-exclusives/lead-researcher-highlights-tisagenlecleucel-benefit-in-younger-leukemia-patients